News
TARO
42.21
-0.13%
-0.06
Weekly Report: what happened at TARO last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at TARO last week (0311-0315)?
Weekly Report · 03/18 09:16
Weekly Report: what happened at TARO last week (0304-0308)?
Weekly Report · 03/11 09:16
Taro Pharmaceutical Industries is Now Oversold (TARO)
NASDAQ · 03/06 16:55
Estée Lauder, Reckitt fall amid cancer risk in acne treatments
Shares of Estée Lauder, Reckitt fall amid cancer risk in acne treatments. Independent U.S. Lab says it found high levels of cancer-causing chemical benzene in some of the companies' treatments. The chemical can cause leukemia in high amounts. Estee Lauder and Reckitt both lost 2% in pre-market trading.
Seeking Alpha · 03/06 13:44
Weekly Report: what happened at TARO last week (0226-0301)?
Weekly Report · 03/04 09:16
Weekly Report: what happened at TARO last week (0219-0223)?
Weekly Report · 02/26 09:18
Weekly Report: what happened at TARO last week (0212-0216)?
Weekly Report · 02/19 09:18
Weekly Report: what happened at TARO last week (0205-0209)?
Weekly Report · 02/12 09:17
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Taro Pharmaceutical Industries Ltd. To Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders will receive $43.00 in cash for each share. KSF is seeking to determine whether the consideration undervalues the Company.
Barchart · 02/06 19:09
Weekly Report: what happened at TARO last week (0129-0202)?
Weekly Report · 02/05 09:18
Krensavage Asset Management Remains Opposed to Sun Pharma's Predatory Bid for Taro Pharma
Krensavage Asset Management is the largest minority shareholder of Taro Pharmaceutical Industries Ltd. The firm is opposed to Sun Pharmaceutical Industries' inadequate bid to take Taro private. The company's CEO says Sun's bid is too low for Taro. Taro is a publicly traded company.
Benzinga · 01/30 12:07
Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro
Krensavage Asset Management says Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries is inadequate. Sun's offer amounts to a 9% discount to the value of Taro's tangible assets. Sun is valuing Taro at $1.6 billion.
PR Newswire · 01/30 12:00
Weekly Report: what happened at TARO last week (0122-0126)?
Weekly Report · 01/29 09:17
Taro Pharmaceutical Inds Ltd: Report of foreign issuer
Press release · 01/26 18:23
Taro Pharmaceutical Indus Q3 2024 GAAP EPS $0.54 Beats $0.30 Estimate
Taro Pharmaceutical Indus reported quarterly earnings of $0.54 per share. The company reported quarterly sales of $157.10 million which beat the analyst consensus estimate of $154.91 million by 1.42%. The company's sales for the quarter were 12.86 percent higher than the same period last year.
Benzinga · 01/25 22:07
Taro Pharmaceutical Indus Q3 Sales $157.10M Beat $154.91M Estimate
Benzinga · 01/25 22:07
Taro Provides Results for December 31, 2023
Taro Pharmaceutical Industries Ltd. Announced that it has entered into a definitive merger agreement with Sun Pharmaceutical Industries Limited on January 17, 2024. The company reported results for the quarter and nine months ended December 31, 2023. Taro reported sales of $157.1 million in the quarter, up 12.9%.
Barchart · 01/25 16:06
Earnings Scheduled For January 25, 2024
Nokia is projected to report quarterly earnings at $0.15 per share on revenue of $7.05 billion. Other companies expected to report before the bell include Popular, NextEra Energy and Southwest Airlines. The Dow Jones Industrial Average is expected to post earnings for the fourth quarter.
Benzinga · 01/25 10:51
Taro Pharmaceutical Q3 2024 Earnings Preview
Seeking Alpha · 01/24 22:35
More
Webull provides a variety of real-time TARO stock news. You can receive the latest news about Taro Pharmaceutical Inds Ltd through multiple platforms. This information may help you make smarter investment decisions.
About TARO
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.